SMS Lifesciences India Reports Q1 Results, Schedules AGM Aug 11, 2025
SMS Lifesciences India Shareholders Approve Six Resolutions, Including Name Change and Executive Reappointment Aug 01, 2025
More news about SMS Lifesciences
16Jul 25
SMS Lifesciences Receives VAI Status from USFDA for API Facility in Telangana
SMS Lifesciences India Limited has received Voluntary Action Indicated (VAI) status from the USFDA for its API manufacturing facility in Kazipally, Telangana. The Establishment Inspection Report with VAI status was received on July 15, 2025. This status indicates general compliance with good manufacturing practices, with minor issues to be addressed. The VAI classification allows the facility to continue operations and export products to the US without significant regulatory hurdles. Company Secretary Trupti Ranjan Mohanty stated that this reaffirms their commitment to global quality standards and enables access to regulated markets.
14Jul 25
SMS Lifesciences Unveils ₹145 Crore Investment Plan to Boost Specialized API Production
SMS Lifesciences India Limited plans to invest ₹145 crore to expand production of specialized Active Pharmaceutical Ingredients (APIs). The company aims for global sector leadership by FY 2028 through backward integration and USFDA-compliant manufacturing. Recent financial highlights include a 12.67% increase in consolidated revenue to ₹344.72 crore and a 196.04% rise in PAT to ₹18.73 crore for FY 2025. The company plans to expand its product portfolio to over 50 products by FY 2028. Recent regulatory achievements include successful USFDA audits of its manufacturing plants. SMS Lifesciences continues to invest in R&D, spending ₹6.30 crore in FY 2025 and filing seven Drug Master Files with the USFDA.
29May 25
SMS Lifesciences India Reports Decline in Q4 Profit
SMS Lifesciences India's Q4 financial results show a significant decline in net profit to ₹30.00 crore, down 49% from ₹59.00 crore in the previous year. Revenue remained relatively stable at ₹891.00 crore, a slight 1% decrease from ₹900.00 crore. The stark contrast between steady revenue and falling profits suggests potential increases in operational costs or other factors affecting profitability in the pharmaceutical sector.
09May 25
SMS Lifesciences India's API Facility Inspection by USFDA Concludes with One Observation
SMS Lifesciences India Limited's Active Pharmaceutical Ingredient (API) manufacturing facility in Telangana underwent a USFDA inspection, concluding with only one observation. This outcome indicates strong regulatory compliance and could boost market confidence and export potential for the company. The management is expected to address the single observation promptly, reinforcing their commitment to maintaining high-quality standards in API manufacturing.